Seeing Is Believing

Currently out of the existing stock ratings of Alan Carr, 108 are a BUY (92.31%), 7 are a HOLD (5.98%), 2 are a SELL (1.71%).
Analyst Alan Carr, carries an average stock price target met ratio of 60.61% that have a potential upside of 37.03% achieved within 458 days. Previously, Alan Carr worked at NEEDHAM.
Alan Carr’s has documented 222 price targets and ratings displayed on 29 stocks. The coverage was on Healthcare, Industrials sectors.
Most recent stock forecast was given on RYTM, Rhythm Pharmaceuticals at 11-Dec-2025.
Analyst best performing recommendations are on CARA (CARA THERAPEUTIC).
The best stock recommendation documented was for ICPT (INTERCEPT PHARMACEUTICALS) at 1/10/2014. The price target of $320 was fulfilled within 4 days with a profit of $125.83 (28.22%) receiving and performance score of 70.56.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 17-Sep-2018
$110
$64.25 (140.44%)
$105
16 days ago
(17-Mar-2026)
27/33 (81.82%)
$59.91 (119.60%)
235
Buy Since 28-Oct-2019
$76
$30.25 (66.12%)
$74
1 months 16 days ago
(17-Feb-2026)
2/16 (12.5%)
$22.83 (42.94%)
24
Hold Since 12-Feb-2025
$45
$-0.75 (-1.64%)
$40
1 months 20 days ago
(13-Feb-2026)
1/7 (14.29%)
$-8.07 (-15.21%)
47
Buy Since 16-Feb-2022
$82
$36.25 (79.23%)
$80
1 months 20 days ago
(13-Feb-2026)
8/27 (29.63%)
$28.93 (54.51%)
214
Buy Since 14-Feb-2025
$74
$28.25 (61.75%)
$99
1 months 20 days ago
(13-Feb-2026)
2/5 (40%)
$20.93 (39.44%)
22
Which stock is Alan Carr is most bullish on?
What Year was the first public recommendation made by Alan Carr?